{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:08:15Z","timestamp":1791497295492,"version":"4.3.4"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1053\/j.seminhematol.2024.05.002","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T06:58:58Z","timestamp":1715324338000},"page":"194-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lessons learned from the E\u00b5-TCL1 mouse model of CLL"],"prefix":"10.1053","volume":"61","author":[{"given":"Alessia","family":"Floerchinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5155-663X","authenticated-orcid":false,"given":"Martina","family":"Seiffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1053\/j.seminhematol.2024.05.002_bib0001","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.002_bib0002","doi-asserted-by":"crossref","first-page":"e2071","DOI":"10.1038\/cddis.2015.419","article-title":"TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia","volume":"7","author":"Bresin","year":"2016","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.002_bib0003","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3727\/105221615X14181438356256","article-title":"The long journey of TCL1 transgenic mice: lessons learned in the last 15 years","volume":"16","author":"Pekarsky","year":"2015","journal-title":"Gene Expr"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.002_bib0004","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/j.seminhematol.2014.05.001","article-title":"Murine genetically engineered and human xenograft models of chronic lymphocytic leukemia","volume":"51","author":"Chen","year":"2014","journal-title":"Semin Hematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.05.002_bib0005","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1182\/blood-2009-03-208256","article-title":"High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia","volume":"114","author":"Herling","year":"2009","journal-title":"Blood"},{"issue":"31","key":"10.1053\/j.seminhematol.2024.05.002_bib0006","doi-asserted-by":"crossref","first-page":"11713","DOI":"10.1073\/pnas.0604564103","article-title":"B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia","volume":"103","author":"Yan","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.05.002_bib0007","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2014-07-587790","article-title":"Two types of BCR interactions are positively selected during leukemia development in the E\u03bc-TCL1 transgenic mouse model of CLL","volume":"125","author":"Iacovelli","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.05.002_bib0008","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2014-05-577122","article-title":"Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy","volume":"124","author":"Simonetti","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.05.002_bib0009","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/leu.2011.111","article-title":"Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL","volume":"25","author":"Hofbauer","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.002_bib0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/leu.2016.322","article-title":"Antigen receptor stereotypy in chronic lymphocytic leukemia","volume":"31","author":"Stamatopoulos","year":"2017","journal-title":"Leukemia"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.05.002_bib0011","doi-asserted-by":"crossref","first-page":"E1500","DOI":"10.1073\/pnas.1300616110","article-title":"Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling","volume":"110","author":"Chen","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.002_bib0012","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41375-018-0260-4","article-title":"Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development","volume":"33","author":"Zaborsky","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.002_bib0013","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41375-021-01381-4","article-title":"Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients","volume":"36","author":"\u00d6zt\u00fcrk","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.002_bib0014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/gm451","article-title":"Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics","volume":"5","author":"Landau","year":"2013","journal-title":"Genome Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.002_bib0015","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3324\/haematol.2019.217307","article-title":"Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription","volume":"105","author":"Edelmann","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.002_bib0016","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/genes8040116","article-title":"The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects","volume":"8","author":"Nguyen","year":"2017","journal-title":"Genes (Basel)"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.002_bib0017","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/modpathol.2016.35","article-title":"The clinical significance of 8q24\/MYC rearrangement in chronic lymphocytic leukemia","volume":"29","author":"Li","year":"2016","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.002_bib0018","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1538\/expanim.58.141","article-title":"Genetic differences among C57BL\/6 substrains","volume":"58","author":"Mekada","year":"2009","journal-title":"Experiment Anim"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.05.002_bib0019","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/s41375-018-0332-5","article-title":"Rejection of adoptively transferred E\u00b5-TCL1 chronic lymphocytic leukemia cells in C57BL\/6 substrains or knockout mouse lines","volume":"33","author":"\u00d6zt\u00fcrk","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.002_bib0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2012.12.003","article-title":"Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo","volume":"23","author":"Lutzny","year":"2013","journal-title":"Cancer cell"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.002_bib0021","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2016.09.007","article-title":"LYN kinase in the tumor microenvironment is essential for the progression of chronic lymphocytic leukemia","volume":"30","author":"Nguyen","year":"2016","journal-title":"Cancer cell"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.05.002_bib0022","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.4049\/jimmunol.1800241","article-title":"Chronic lymphocytic leukemia-derived IL-10 suppresses antitumor immunity","volume":"200","author":"Alhakeem","year":"2018","journal-title":"J Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.002_bib0023","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1172\/JCI99386","article-title":"PI3K p110\u03b4 inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression","volume":"129","author":"Dong","year":"2019","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.002_bib0024","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/leu.2015.305","article-title":"Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo","volume":"30","author":"Hanna","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.002_bib0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cell.2009.09.033","article-title":"Induction of intestinal Th17 cells by segmented filamentous bacteria","volume":"139","author":"Ivanov","year":"2009","journal-title":"Cell"},{"issue":"6264","key":"10.1053\/j.seminhematol.2024.05.002_bib0026","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.002_bib0027","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s40425-019-0574-4","article-title":"Exploring the emerging role of the microbiome in cancer immunotherapy","volume":"7","author":"Fessler","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.seminhematol.2024.05.002_bib0028","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.284693","article-title":"The diversity of the microbiome impacts chronic lymphocytic leukemia development in mice and humans","author":"Faitov\u00e1","year":"2024","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.05.002_bib0029","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3324\/haematol.2021.280455","article-title":"The gut microbiome in patients with chronic lymphocytic leukemia","volume":"107","author":"Faitov\u00e1","year":"2022","journal-title":"Haematologica"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.05.002_bib0030","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.05.002_bib0031","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","article-title":"Myeloid-derived suppressor cells: linking inflammation and cancer","volume":"182","author":"Ostrand-Rosenberg","year":"2009","journal-title":"J Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.05.002_bib0032","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028662","article-title":"Cancer inflammation and cytokines","volume":"10","author":"Galdiero","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.002_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1053\/j.seminhematol.2024.05.002_bib0034","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.molimm.2017.11.014","article-title":"Beyond bystanders: myeloid cells in chronic lymphocytic leukemia","volume":"110","author":"Hanna","year":"2019","journal-title":"Mol Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.05.002_bib0035","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.05.002_bib0036","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3324\/haematol.2012.073080","article-title":"The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation","volume":"98","author":"Maffei","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.002_bib0037","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.05.002_bib0038","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41375-021-01249-7","article-title":"Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL","volume":"35","author":"Ferrer","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.05.002_bib0039","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.celrep.2016.01.042","article-title":"Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression","volume":"14","author":"Galletti","year":"2016","journal-title":"Cell Rep"},{"key":"10.1053\/j.seminhematol.2024.05.002_bib0040","article-title":"Phosphoinositide 3-kinase signaling in the tumor microenvironment: what do we need to consider when treating chronic lymphocytic leukemia with PI3K inhibitors?","volume":"11","author":"Aydin","year":"2020","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminhematol.2024.05.002_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.727531","article-title":"Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets\u2014beyond B lymphocytes","volume":"9","author":"Zhu","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.05.002_bib0042","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1080\/10428194.2018.1457147","article-title":"Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia","volume":"59","author":"Pleyer","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.05.002_bib0043","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nature Immunol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.05.002_bib0044","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nature Rev Immunol"},{"key":"10.1053\/j.seminhematol.2024.05.002_bib0045","article-title":"T Cells in chronic lymphocytic leukemia: a two-edged sword","volume":"11","author":"Vlachonikola","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.05.002_bib0046","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41375-020-0873-2","article-title":"T-cells in chronic lymphocytic leukemia: guardians or drivers of disease?","volume":"34","author":"Roessner","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.05.002_bib0047","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.002_sbref0048","author":"Cid","year":"2023","journal-title":"High-dimensional single-cell definition of CLL T cells identifies Galectin-9 as novel immunotherapy target"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.002_bib0049","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2015-02-626754","article-title":"Mechanisms of PD-L1\/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Emicro-TCL1 CLL mouse model","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.05.002_bib0050","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.002_bib0051","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41375-018-0250-6","article-title":"Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.002_bib0052","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/10428194.2019.1660972","article-title":"CD8+ T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion","volume":"61","author":"Lla\u00f3 Cid","year":"2020","journal-title":"Leukemia Lymphoma"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.05.002_bib0053","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.immuni.2021.11.004","article-title":"Interleukin-10 receptor signaling promotes the maintenance of a PD-1(int) TCF-1(+) CD8(+) T cell population that sustains anti-tumor immunity","volume":"54","author":"Hanna","year":"2021","journal-title":"Immunity"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.002_bib0054","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/bloodadvances.2021006941","article-title":"The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia","volume":"7","author":"Sun","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.05.002_bib0055","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood.2021013990","article-title":"Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment","volume":"140","author":"Chen","year":"2022","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.05.002_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136648","article-title":"Evidence for non-cancer-specific T cell exhaustion in the Tcl1 mouse model for chronic lymphocytic leukemia","volume":"22","author":"Parigger","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.002_bib0057","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.002_bib0058","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.13467","article-title":"Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model","volume":"170","author":"Gassner","year":"2015","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.05.002_bib0059","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2012-05-423194","article-title":"Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia","volume":"120","author":"Wiestner","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.002_bib0060","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.05.002_bib0061","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/blood-2014-06-583518","article-title":"OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells","volume":"125","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.05.002_bib0062","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1182\/blood-2014-11-610329","article-title":"The PI3K\/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the E\u00b5-TCL1 mouse model","volume":"125","author":"Blunt","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.05.002_bib0063","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.05.002_bib0064","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood-2010-03-275180","article-title":"The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E\u03bc-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling","volume":"116","author":"Suljagic","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.05.002_bib0065","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/blood-2012-09-457119","article-title":"Targeting the LYN\/HS1 signaling axis in chronic lymphocytic leukemia","volume":"121","author":"ten Hacken","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.05.002_bib0066","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2018881029","article-title":"IGF1R as druggable target mediating PI3K-\u03b4 inhibitor resistance in a murine model of chronic lymphocytic leukemia","volume":"134","author":"Scheffold","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.05.002_bib0067","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3324\/haematol.2019.238154","article-title":"Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice","volume":"106","author":"Hanna","year":"2021","journal-title":"Haematologica"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.05.002_bib0068","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1158\/1078-0432.CCR-17-0650","article-title":"Combined BTK and PI3K\u03b4 inhibition with acalabrutinib and ACP-319 improves survival and tumor control in CLL Mouse Model","volume":"23","author":"Niemann","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.05.002_bib0069","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1182\/bloodadvances.2021004861","article-title":"Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia","volume":"5","author":"Kater","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.05.002_bib0070","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.05.002_bib0071","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.002_bib0072","article-title":"Role of the tumor microenvironment in CLL pathogenesis","author":"vom Stein","year":"2023","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.002_bib0073","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.pharmthera.2014.07.003","article-title":"Microenvironment dependency in chronic lymphocytic leukemia: the basis for new targeted therapies","volume":"144","author":"ten Hacken","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.002_bib0074","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2012-05-431452","article-title":"Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor","volume":"121","author":"Reinart","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.05.002_bib0075","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3324\/haematol.2020.268037","article-title":"Targeting the tumor microenvironment in chronic lymphocytic leukemia","volume":"106","author":"Svanberg","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.002_bib0076","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bbamcr.2015.11.003","article-title":"Tumor microenvironment (TME)-driven immune suppression in B cell malignancy","volume":"1863","author":"Nicholas","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.05.002_bib0077","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.002_bib0078","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.05.002_bib0079","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood-2017-06-792267","article-title":"Dual PD1\/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","volume":"131","author":"Wierz","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.05.002_bib0080","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3343\/alm.2023.0388","article-title":"Current challenges in chimeric antigen receptor T-cell therapy in patients with B-cell lymphoid malignancies","volume":"44","author":"Kim","year":"2024","journal-title":"Ann Lab Med"},{"key":"10.1053\/j.seminhematol.2024.05.002_bib0081","article-title":"Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma","volume":"11","author":"Negishi","year":"2023","journal-title":"Front Pediatr"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.05.002_bib0082","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"10402","key":"10.1053\/j.seminhematol.2024.05.002_bib0083","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.05.002_bib0084","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nature Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.05.002_bib0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000534341","article-title":"Cellular therapy in chronic lymphocytic leukemia: have we advanced in the last decade?","volume":"147","author":"Katz","year":"2024","journal-title":"Acta Haematol"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2024.05.002_bib0086","first-page":"S11","article-title":"Management of relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Woyach","year":"2022","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.05.002_bib0087","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632400060X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632400060X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T13:20:11Z","timestamp":1720531211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719632400060X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S003719632400060X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.05.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lessons learned from the E\u00b5-TCL1 mouse model of CLL","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}